Jennifer Bogert

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease

Reisa A. Sperling, David Henley, Paul Aisen et al. · JAMA Neurology · 2021 · 110 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer’s disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

Gerald Novak, Johannes Streffer, Maarten Timmers et al. · Alzheimer s Research & Therapy · 2020 · 105 citations · Full text

Medicine, Neurology, Pharmacology +17

Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer’s Disease Patients

Nzeera Ketter, H. Robert Brashear, Jennifer Bogert et al. · Journal of Alzheimer s Disease · 2017 · 85 citations · Full text

Medicine, Neurology, Neuroscience +17

Profiling the dynamics of CSF and plasma Aβ reduction after treatment with JNJ‐54861911, a potent oral BACE inhibitor

Maarten Timmers, Bianca Van Broeck, Steven Ramael et al. · Alzheimer s & Dementia Translational Research & Clinical Interventions · 2016 · 60 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +7

Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer's disease

Maarten Timmers, Ina Tesseur, Jennifer Bogert et al. · Neurobiology of Aging · 2019 · 41 citations · Full text

Life Sciences, Neurology, Neuroscience +14